The market size of the Global Artificial Intelligence in Epidemiology Market in the year 2021 is valued at 297.02 million and is predicted to reach 2603.02 million by the year 2030 at an 27.54% CAGR during the forecast period.
Artificial intelligence (AI) is an intelligent system that performs various human intelligence-based operations in domains such as biology, computer science, mathematics, linguistics, psychology, and engineering. These talents include reasoning, learning, and problem-solving. In the healthcare industry, artificial intelligence is used to analyze complex medical data using algorithms and software. Rising public awareness of the significance of technology in chronic disease diagnosis and monitoring will be a significant driving force in the progress of AI applications in epidemiology. As healthcare research and development efforts expand, so will the demand for artificial intelligence in epidemiology labs. The extensive usage and use of AI in drug research and discovery activities is a critical motivator. Pharmaceutical and biotech companies have also increased their R&D investments. This investment interest is driving the adoption of AI systems to follow the progression of syndromic diseases. The growing burden of chronic diseases has increased the need for effective control measures and the development of feasible treatment solutions. Government-backed programs, more significant investment from private investors and venture capitalists, and the creation of AI-focused start-ups worldwide are driving market expansion. Despite the prevalence of the diseases, the high cost of these techniques may impede the growth of the worldwide AI-based critical care market.
Artificial intelligence in the epidemiology market is segmented on the deployment, applications and end users. Based on deployment, the market is segmented into web-based and cloud-based. Based on application, artificial intelligence in the epidemiology market is segmented into infection prediction & forecasting and disease & syndromic surveillance. Based on the end user, artificial intelligence in the epidemiology market is segmented into government & state agencies, research labs, pharmaceutical & biotechnology companies, and healthcare providers.
Based on end users, the healthcare providers segment is accounted as a significant contributor to artificial intelligence in the epidemiology market.
The market's leading segment is healthcare providers. As a result of recent increases in awareness and correction of some common misconceptions about the intake of certain veggies, consumer acceptance and widespread application for equestrian and cow feeding are expected to drive demand for GMO veggies, strengthening segmental development.
The web-based segment witnessed growth at a rapid rate.
Web-based grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the expected time. Adopting web-based software in epidemiology provides various advantages, including the possibility of integrating with other interoperable platforms. Web-based resources are also being developed to give health information and aid decision-making quickly. Such advancements will accelerate the use of AI in web-based epidemiological data analysis.
The North American artificial intelligence in epidemiology market holds a significant revenue share in the region.
The North American artificial intelligence in epidemiology market is expected to register the highest market share in revenue shortly. Because of developments in healthcare IT infrastructure, rising healthcare expenditures, widespread technology use, favourable government efforts, and the presence of numerous key market competitors, The region has seen an increase in the use of AI technologies by federal authorities. The presence of key technology players will also facilitate the efficient integration of AI in epidemiology. Countries such as the United States and Canada are home to big pharmaceutical and biotechnology corporations that invest heavily in research, indicating a promising future for North American AI solution suppliers. Besides, Asia-Pacific is predicted to increase due to significant breakthroughs and development in IT infrastructure and entrepreneurial initiatives specialized in AI-based technologies. Artificial intelligence (AI) is an intelligent system that performs various functions.
Some major key players in the Artificial intelligence in epidemiology market are Cognizant Technology Solutions Corporation, Cerner Corporation (Oracle), Epic Systems Corporation, eClinicalWorks LLC, Alphabet Inc., Komodo Health, Microsoft Corporation, Meditech, Predixion Software, Siemens Healthineers AG, Intel Corporation, Bayer Healthcare, Artificial Intelligence for Medical Epidemiology (AIME), Cardiolyse, and SAS Institute, Inc.